Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Journal of Investigative Medicine

Volumn 59, Issue 6, 2011, Pages 931-937

  Basar, Nurcan ^a   Sen, Nihat ^a   Ozcan, Firat ^a   Erden, Gonul ^b   Kanat, Selcuk ^a   Sokmen, Erdogan ^a   Isleyen, Ahmet ^a   Yuzgecer, Huseyin ^a   Ozlu, Mehmet Fatih ^a   Yildirimkaya, Metin ^b   Maden, Orhan ^a   Covic, Adrian ^c   Johnson, Richard J ^d   Kanbay, Mehmet ^e  

^a Yuksek Ihtisas Education and Research Hospital   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^d UNIVERSITY OF COLORADO   (United States)

^e GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Mortality; Primary percutaneous coronary intervention; ST segment elevation myocardial infarction; Uric acid

Indexed keywords

URIC ACID;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; URIC ACID BLOOD LEVEL;

EID: 84863012830     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318214ebaf     Document Type: Article

References (59)

1. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-1190. (Pubitemid 36706063)
2. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-6862. (Pubitemid 12216861)
3. Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131-139.
4. Reyes AJ, Leary WP. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid? Cardiovasc Drugs Ther. 2002;16(6):485-487. (Pubitemid 36520995)
5. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-865. (Pubitemid 27208159)
6. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555(Pt 3):589-606. (Pubitemid 38404582)
7. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-2516. (Pubitemid 44901524)
8. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart. 2005;91(6):707-709. (Pubitemid 40769203)
9. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-3562.
10. Yu MA, Sanchez-Lozada LG, Johnson RJ, et al. Uric acid: an inducer of oxidative stress and renin angiotensin system in human vascular endothelial cells. J Hypertension. In press.
11. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-1293. (Pubitemid 36706079)
12. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888-2897. (Pubitemid 35386908)
13. Cheng TH, Lin JW, Chao HH, et al. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol. 2010;139:42-49.
14. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227-1233. (Pubitemid 350193621)
15. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-59. (Pubitemid 41828266)
16. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA. 2008;300(8):922-930.
17. Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3(1):73-81.
18. Muir SW, Harrow C, Dawson J, et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2008;39(12):3303-3307.
19. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266(13):8604-8608. (Pubitemid 21906552)
20. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol. 2002;282(6):F991-F997. (Pubitemid 34654464)
21. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol. 2008;295(4):F1134-F1141.
22. Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269-275.
23. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237-247. (Pubitemid 40019245)
24. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69(14):1418-1423. (Pubitemid 47511463)
25. Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(5):498-503. (Pubitemid 46602011)
26. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51(2):172-209.
27. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101(2):125-130. (Pubitemid 30044249)
28. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93(2):223-228. (Pubitemid 26031478)
29. Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J. 1997;18(4):618-624. (Pubitemid 27182355)
30. Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995;130(2):239-243.
31. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202-1209.
32. Van de Werf F, Ardissino D, Betriu A, et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:28-66.
33. Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 1993;87(6):1829-1839. (Pubitemid 23165624)
34. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879-888. (Pubitemid 26074824)
35. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999;99(15):1945-1950. (Pubitemid 29183889)
36. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24(2):384-391. (Pubitemid 24246537)
37. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. J Am Coll Cardiol. 2003;42(1):7-16. (Pubitemid 36760755)
38. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351. (Pubitemid 46685903)
39. Brodov Y, Chouraqui P, Goldenberg I, et al. Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology. 2009;114(4):300-305.
40. Dunkelgrun M, Welten GM, Goei D, et al. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am J Cardiol. 2008;102(7):797-801.
41. Hiyamuta K, Toshima H, Koga Y, et al. Relationship between coronary risk factor and arteriographic feature of coronary atherosclerosis. Jpn Circ J. 1990;54(4):442-447. (Pubitemid 20315534)
42. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89(1):12-17. (Pubitemid 34066579)
43. Madsen TE, Muhlestein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005;25(1):45-49. (Pubitemid 40529275)
44. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87(12):1411-1414. (Pubitemid 32523032)
45. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503-1507. (Pubitemid 44305733)
46. Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121(1):11-18. (Pubitemid 15150683)
47. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141(7):637-644.
48. Liese AD, Hense HW, Lowel H, et al. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999;10(4):391-397. (Pubitemid 29288237)
49. Lazzeri C, Valente S, Chiostri M, et al. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138(2):206-209.
50. Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96(4):489-495. (Pubitemid 41132762)
51. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85(5):1699-1705.
52. Suenari K, Shiode N, Shirota K, et al. Predictors and long-term prognostic implications of angiographic slow/no-flow during percutaneous coronary intervention for acute myocardial infarction. Intern Med. 2008;47(10):899-906. (Pubitemid 351936185)
53. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45(9):1397-1405. (Pubitemid 40615609)
54. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol. 2007;292(4):F1238-F1244. (Pubitemid 46572443)
55. Gibson CM, Murphy SA, Kirtane AJ, et al. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(5):980-987. (Pubitemid 39165130)
56. Ma XL, Tsao PS, Viehman GE, et al. Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ Res. 1991;69(1):95-106.
57. Many A, Hubel CA, Roberts JM. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174 (1 Pt 1):288-291. (Pubitemid 26037726)
58. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94(7):932-935. (Pubitemid 39349561)
59. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174-1181.